Theratechnologies has entered into a definitive agreement to be acquired by CB Biotechnology, an affiliate of Future Pak, for US$3.01 per share in cash, plus contingent value rights potentially totaling US$1.19 per share, valuing the transaction at approximately US$254 million.

Information on the Target

Theratechnologies Inc. (TSX: TH, NASDAQ: THTX) is a commercial-stage biopharmaceutical company headquartered in Montreal, Canada. The company specializes in the development and commercialization of innovative therapies that aim to improve patient care and redefine standards in medical treatment. With a strong commitment to advancing healthcare, Theratechnologies has established a portfolio of products and is focused on delivering meaningful health outcomes for patients.

Recently, Theratechnologies announced a binding arrangement agreement with CB Biotechnology, LLC, affiliated with Future Pak, LLC, a contract manufacturer of pharmaceutical and nutraceutical products. Under this agreement, CB Biotechnology will acquire all outstanding shares of Theratechnologies at a price of US$3.01 per share in cash, plus contingent value rights (CVRs) that could provide additional payments based on the achievement of specific milestones.

Industry Overview in Canada

The biopharmaceutical industry in Canada is characterized by its robust infrastructure and a focus on innovation. Canada is home to a diverse range of biopharmaceutical enterprises engaged in research and development, manufactu